Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2060-2068

  Katayama, Ryohei ^a   Koike, Sumie ^a   Sato, Shigeo ^a   Sugimoto, Yoshikazu ^a,b   Tsuruo, Takashi ^a   Fujita, Naoya ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; BREAST CANCER RESISTANCE PROTEIN; DOFEQUIDAR FUMARATE; IRINOTECAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; QUINOLINE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; HUMANS; METHOTREXATE; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; QUINOLINES;

EID: 71049189661     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01288.x     Document Type: Article

References (35)

1. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev 2005, 5:275-84.
2. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183:1797-806.
3. Zhou S, Schuetz JD, Bunting KD. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-34.
4. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002, 99:507-12.
5. Barile L, Messina E, Giacomello A, Marban E. Endogenous cardiac stem cells. Prog Cardiovasc Dis 2007, 50:31-48.
6. Kato K, Yoshimoto M, Kato K. Characterization of side-population cells in human normal endometrium. Hum Reprod 2007, 22:1214-23.
7. Chiba T, Kita K, Zheng YW. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-51.
8. Haraguchi N, Utsunomiya T, Inoue H. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24:506-13.
9. Hirschmann-Jax C, Foster AE, Wulf GG. A distinct " side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004, 101:14 228-33.
10. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004, 101:781-6.
11. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41:1967-72.
12. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-34.
13. Suzuki T, Fukazawa N, San-nohe K, Sato W, Yano O, Tsuruo T. Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. J Med Chem 1997, 40:2047-52.
14. Naito M, Matsuba Y, Sato S, Hirata H, Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res 2002, 8:582-8.
15. Nakanishi O, Baba M, Saito A. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res 1997, 9:61-9.
16. Sato W, Fukazawa N, Nakanishi O. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995, 35:271-7.
17. Saeki T, Nomizu T, Toi M. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol 2007, 25:411-17.
18. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997, 8:837-55.
19. Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 1999, 288:735-41.
20. Jansen WJ, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 1998, 77:359-65.
21. Kawabata S, Oka M, Shiozawa K. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001, 280:1216-23.
22. Kage K, Tsukahara S, Sugiyama T. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 2002, 97:626-30.
23. Narasaki F, Oka M, Fukuda M. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Cancer Chemother Pharmacol 1997, 40:425-32.
24. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000, 60:47-50.
25. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005, 7:E118-33.
26. Allen JD, van Loevezijn A, Lakhai JM. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002, 1:417-25.
27. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92:1295-302.
28. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-61.
29. Ito K, Bernardi R, Morotti A. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-8.
30. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-74.
31. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006, 66:4553-7.
32. Piccirillo SG, Reynolds BA, Zanetti N. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-5.
33. Frank NY, Margaryan A, Huang Y. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65:4320-33.
34. Schatton T, Murphy GF, Frank NY. Identification of cells initiating human melanomas. Nature 2008, 451:345-9.
35. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007, 67:4827-33.